Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Expanded Access Program for Aztreonam Lysine for Inhalation in Canadian Patients With Cystic Fibrosis (EAP)

This treatment has been approved for sale to the public.
Sponsor:
Information provided by (Responsible Party):
Gilead Sciences
ClinicalTrials.gov Identifier:
NCT00989807
First received: October 2, 2009
Last updated: December 12, 2012
Last verified: October 2012
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This treatment has been approved for sale to the public.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: No date given